Chris Shibutani
Stock Analyst at Goldman Sachs
(3.59)
# 819
Out of 5,241 analysts
94
Total ratings
56.25%
Success rate
24.94%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $138 → $100 | $48.78 | +105.00% | 2 | Apr 1, 2025 | |
| ERAS Erasca | Maintains: Buy | $3.5 → $3 | $10.32 | -70.93% | 7 | Mar 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Sell | $20 → $15 | $7.44 | +101.61% | 4 | Mar 14, 2025 | |
| ALKS Alkermes | Maintains: Buy | $30 → $32 | $37.00 | -13.51% | 7 | Feb 14, 2025 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $87.79 | +56.05% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $19.36 | +70.45% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $566.80 | -46.72% | 4 | Nov 1, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $52.41 | -2.69% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $230.00 | -32.61% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $12.74 | -68.60% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $13.42 | +49.03% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $1,021.41 | -29.22% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $11.99 | +116.85% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $154.36 | -0.88% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $213.76 | -19.07% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $67.58 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $58.31 | +18.33% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $21.73 | -40.17% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $147.30 | -84.39% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $78.14 | -33.45% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $25.66 | +133.83% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $5.65 | +218.58% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $20.30 | -16.26% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.09 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $6.81 | - | 4 | Jan 24, 2018 |
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $138 → $100
Current: $48.78
Upside: +105.00%
Erasca
Mar 21, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $10.32
Upside: -70.93%
Seres Therapeutics
Mar 14, 2025
Maintains: Sell
Price Target: $20 → $15
Current: $7.44
Upside: +101.61%
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30 → $32
Current: $37.00
Upside: -13.51%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $87.79
Upside: +56.05%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $19.36
Upside: +70.45%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $566.80
Upside: -46.72%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $52.41
Upside: -2.69%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $230.00
Upside: -32.61%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $12.74
Upside: -68.60%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $13.42
Upside: +49.03%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $1,021.41
Upside: -29.22%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $11.99
Upside: +116.85%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $154.36
Upside: -0.88%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $213.76
Upside: -19.07%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $67.58
Upside: -
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $58.31
Upside: +18.33%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $21.73
Upside: -40.17%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $147.30
Upside: -84.39%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $78.14
Upside: -33.45%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $25.66
Upside: +133.83%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $5.65
Upside: +218.58%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $20.30
Upside: -16.26%
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $6.09
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $6.81
Upside: -